Enterprise Value

87.91M

Cash

272.7M

Avg Qtr Burn

N/A

Short % of Float

7.63%

Insider Ownership

20.71%

Institutional Own.

54.32%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AAV Capsids (Pfizer) Details
Neurological disorder

Phase 1

Update

AAV Capsids (Novartis) Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

Phase 1

Initiation

AAV Capsids Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

VY-AADC (NBIb-1817) Details
Parkinson's disease, Central nervous system illness

Failed

Discontinued

VY-HTT01 Details
Huntington's disease

Failed

Discontinued